42
Participants
Start Date
September 30, 2020
Primary Completion Date
February 16, 2023
Study Completion Date
October 13, 2023
parsaclisib
parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
Red Cross Nagoya Daini Hospital, Nagoya
Ogaki Municipal Hospital, Ōgaki
Ja-Aichi Anjo Kosei Hospital, Anjo
University of Fukui Hospital, Fukui
Jcho Kyushu Hospital, Fukuoka
National Hospital Organization Kyushu Cancer Center, Fukuoka
Fukushima Medical University Hospital, Fukushima
Kansai Medical University Hospital, Hirakata
Hokuyukai Sapporo Hokuyu Hospital, Hokkaido
Hyogo College of Medicine Hospital, Hyōgo
Nho Mito Medical Center, Ibaraki
Tokai University Hospital, Isehara
Jiaikai Imamura General Hospital, Kagoshima
Kobe City Medical Center General Hospital, Kobe
University Hospital Kyoto Prefectural University of Medicine, Kyoto
Nho Matsumoto Medical Center, Matsumoto
Nho Shikoku Cancer Center, Matsuyama
Nagano Red Cross Hospital, Nagano
National Hospital Organization Nagoya Medical Center, Nagoya
Japanese Red Cross Nagoya Daini Hospital, Nagoya
Tenri Hospital, Nara
Miyagi Cancer Center, Natori
Niigata Cancer Center Hospital, Niigata
Okayama University Hospital, Okayama
Nho Hokkaido Cancer Center, Sapporo
Tohoku University Hospital, Sendai
Shizuoka Cancer Center, Shizuoka
Nippon Medical School Hospital, Tokyo
Yokohama Municipal Citizens Hospital, Yokohama
Yokohama City University Medical Center, Yokohama
Lead Sponsor
Incyte Biosciences Japan GK
INDUSTRY